Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06099730 · ClinicalTrials.gov registry record · NA

Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF

A NA study of Atrial Fibrillation, sponsored by Massachusetts General Hospital.

Active
Registry status
NA
Development phase
360
Enrollment target
7
Study locations

NCT06099730: Active NA study of Atrial Fibrillation, sponsored by Massachusetts General Hospital.

NCT06099730 is a NA study of Atrial Fibrillation that is active but no longer recruiting, run by Massachusetts General Hospital. The registered enrollment target is 360 participants, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower). The trial reports 7 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06099730, a NA study of Atrial Fibrillation, is active but no longer recruiting, sponsored by Massachusetts General Hospital.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
360 participants
Enrollment target
7
Study locations

Study Summary

The primary objective of this clinical investigation is to demonstrate the safety and 12-month effectiveness of pulmonary vein isolation (PVI) and posterior LA wall isolation in the treatment of subjects with symptomatic paroxysmal and persistent atrial fibrillation using the pulsed field ablation with the VARIPULSE™ catheter and the TRUPULSE™ generator.

Conditions Studied

Interventions

  • DEVICE Pulsed Field Ablation (PFA)

Study Locations (7)

Massachusetts

  • Massachusetts General Hospital - Boston
  • Beth Israel Deaconess Medical Center - Boston

New York

  • Mount Sinai Hospital - New York
  • Montefiore Medical Center - New York

Arkansas

  • St. Bernard's Heart and Vascular Center - Jonesboro

Ohio

  • Cleveland Clinic - Cleveland

Texas

  • Texas Cardiac Arrhythmia Institute/Research Foundation - Austin

Trial Details

FieldValue
Enrollment Target 360 participants
Start Date 2023-12-14
Est. Completion 2026-11
Phase NA
Massachusetts General Hospital

2,032 total trials

What the registry record for NCT06099730 still lists

NCT06099730 is an interventional study that assigns participants to a tested intervention. The registered 360 participants enrollment target is mid-sized for trials with a published cap, below the 2,995-participant average among 202 other Atrial Fibrillation trials with a reported enrollment target (88% lower).

The record links to 1 condition, with Atrial Fibrillation appearing as the primary indexed condition, and to 1 intervention - of which Pulsed Field Ablation (PFA) is the first listed.

NCT06099730 lists 7 locations in 5 states (Massachusetts, New York, Arkansas).

Frequently Asked Questions

What is clinical trial NCT06099730 about?

NCT06099730 is a clinical study titled "Safety and Effectiveness of Pulmonary Vein isOLation And posterioR Wall Ablation wIth pulSed Field Energy in Patients With Paroxysmal and Persistent AF". The primary objective of this clinical investigation is to demonstrate the safety and 12-month effectiveness of pulmonary vein isolation (PVI) and posterior LA wall isolation in the treatment of subjects with symptomatic paroxysmal and persistent atrial fibrillation using the pulsed field ablation w...

What is the current status of trial NCT06099730?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 360 participants. The study started on 2023-12-14. Estimated completion is 2026-11.

What conditions does trial NCT06099730 study?

This clinical trial studies the following conditions: Atrial Fibrillation.

What interventions are being tested in trial NCT06099730?

The interventions under investigation include: Pulsed Field Ablation (PFA) (DEVICE).

Who is sponsoring clinical trial NCT06099730?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06099730 being conducted?

This trial has 7 study locations across Arkansas, Massachusetts, New York, Ohio, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Atrial Fibrillation

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT06099730's enrollment target sits among peer trials

360 73rd of 202 higher than 128 of 202 other Atrial Fibrillation trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Atrial Fibrillation trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02747836 · 360 participants

    Ultrasound Analysis of Human Carpal Tunnel System

  • NCT04089046 · 360 participants · NA

    Telemedicine Enhanced Asthma Management - Uniting Providers for Teens (TEAM-UP for Teens)

  • NCT04130503 · 360 participants · NA

    The Recovery in Stroke Using PAP Study

  • NCT04907643 · 360 participants · NA

    Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06099730, the US trial registry maintained by the National Library of Medicine. NCT06099730 (mid enrollment · multi site footprint · active not recruiting) retrieved and formatted by PlainTrial, see methodology.